Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 16/20 | 0.75 |
| ▸ | CA9 | Q16790 | 16/20 | 0.75 |
| ▸ | CDC25A | P30304 | 1/20 | 0.61 |
| ▸ | CDC25B | P30305 | 1/20 | 0.61 |
| ▸ | CDC25C | P30307 | 1/20 | 0.61 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.61 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3341735 | 0.87 | CA12 (0.83) | CA12CA9CSNK2A1MEN1KMT2A | |
| SCHEMBL3338338 | 0.84 | CA12 (0.88) | CA12CA9CSNK2A1MEN1KMT2A | |
| SCHEMBL3337386 | 0.84 | CA12 (1.00) | CA12CA9CSNK2A1MEN1KMT2A | |
| SCHEMBL3338101 | 0.81 | MAPT (0.67) | MEN1KMT2ALMNAGAAMAPT | |
| SCHEMBL3338725 | 0.80 | CA12 (0.81) | CA12CA9CSNK2A1MEN1KMT2A | |
| SCHEMBL4304956 | 0.76 | CDC25A (1.00) | CA12CA9CDC25ACDC25BCDC25C | |
| SCHEMBL3341872 | 0.76 | MAPT (0.61) | CA12CA9MEN1KMT2ALMNA | |
| SCHEMBL3339186 | 0.75 | NPC1 (0.78) | MEN1KMT2ALMNAGAAMAPT | |
| SCHEMBL24711240 | 0.74 | CA12 (0.81) | CA12CA9CSNK2A1MEN1KMT2A | |
| SCHEMBL3337373 | 0.74 | PTGS2 (0.64) | CA12CA9CSNK2A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410152-B2 | Thiazolhydrazides for treatment of neurodegenerative diseases | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) | 2013-04-02 | — | — | US | disclosed |
| US-20100151064-A1 | THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | TECHNISCHE UNIVERSITAT DARMSTADT (DE) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100151064-A1 | THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | HTT, MAPT, SNCA | CA12 3769/4885CA9 3189/4885CDC25A 4288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.